We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Test Identifies Pregnant Women at Risk for Preeclampsia

By Labmedica staff writers
Posted on 26 Mar 2008
A test that identifies pregnant women at risk of developing preeclampsia is performed from as early as the seventh week of pregnancy, and it predicts the appearance of the condition six months later. More...
The test results provide the physician with a useful tool to evaluate the surveillance and management of the pregnant woman.

According to the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), preeclampsia affects 5-7% of all pregnant women and represents a serious challenge for obstetricians, and prenatal and diagnostic laboratories. This disorder can result in loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver, and cardiovascular malfunctioning. It is a rapidly progressive condition characterized by sudden hypertension and an elevated protein level in urine.

Scientists from Diagnostic Technologies (Yokne'am Illit, Israel) developed a breakthrough technology that could help doctors identify pregnant women at risk of developing preeclampsia. The early detection is performed about 20 weeks before symptoms develop, and is based on the use of a simple blood test, which determines the level of a protein produced by the placenta--placenta protein 13 (PP13).

"Preeclampsia is the second most frequent cause of maternal death in pregnancy, but to our disappointment the dimension of the problem is not known to the public. Many women, pregnant or not, are unaware of the real risk,” said developmental neurobiologist Dr. Hamutal Meiri, CEO of Diagnostic Technologies. Early detection gives rise to prevention and management of the risk due to better pregnancy management and preventive treatment.”

The company is now working towards completing a study of the test with the aim of achieving U.S. Food and Drug Administration (FDA; Rockville, MD, USA) approval. Dr. Meiri said that they plan to complete development of a product dedicated to tailor medication to women at high risk for preeclampsia, and to identify families with a genetic disorder that predisposes to preeclampsia.


Related Links:
U.S. Centers for Disease Control and Prevention
Diagnostic Technologies
U.S. Food and Drug Administration

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.